Clinical experience results with clindamycin 1% benzoyl peroxide 5% gel as monotherapy and in combination

Journal of Drugs in Dermatology, March-April, 2005 by Joseph B. Bikowski

Disclosure: Dr. Bikowski receives honoraria and/or consultation fees from and/or may participate as a speaker for the following companies: Allergan, Aventis, Berlex, Biogen-Idec, CollaGenex, Dermik, Fujisawa, Galderma, GlaxoSmithKline, Healthpoint, Medicis, Novartis, Stiefel, 3M, and Warner Chilcott.

References

1. Gollnick H. Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs. 2003;63:1579-1596.

2. Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect Immun. 1995;63:3158-3165.

3. Webster GF, Leyden JJ. Characterization of serum-independent polymorphonuclear leukocyte chemotactic factors produced by Propionibacterium acnes. Inflammation. 1980;4:261-269.

4. Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol. 1996;106:176-182.

5. Leyden J, Kaidbey K, Levy SF. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. An in vivo comparative study. Am J Clin Dermatol. 2001;2:263-266.

6. Eady EA, et al. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br J Dermatol. 1994;131:331-336.

7. Eady EA, et al. The effect of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol. 1996;134:107-113.

8. Harkaway KS, et al. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol. 1992;126:586-590.

9. Leyden JJ, Levy S. The development of antibiotic resistance in Propionibacterium acnes. Cutis. 2001;67:21-24.

10. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49:S200-S210.

11. Differin[R] (adapalene) Gel [package insert]. Fort Worth, Texas: Galderma Laboratories, LP. May, 2004.

12. Ellis CN, et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis. 2001;67:13-20.

13. Chalker DK, et al. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol. 1983;9:933-936.

14. Lookingbill DP, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol. 1997; 37:590-595.

15. Leyden JJ, et al. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg. 2001;5:37-42.

16. Russell JJ. Topical therapy for acne. Am Family Physician. 2000;61:357-366.